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HUGGINS, Miller and Jensen (1949) studied the thermocoagulability of the
serum protein in health and disease in the presence of an extrinsic inhibitor-
iodoacetic acid. Their results, however, while showing an abnormal behaviour
fo'r mahgnant and certain non-mahgnant diseases, tend to establish a seeming
relationship between cancer and tuberculosis. The purpose of this paper is to
clarify the difference in behaviour of the serum from cancer and tuberculosis
patients in determining the type of
" Index." The selection of tuberculosis
serum waspurely fortuitous. It arose from a desire for a
"positive
" control, as
well as a negative, because the tuberculosis serum was supposed to resemble
cancer in this test. Firom the experiments described here it would appear that
a
CC positive
" test encountered in tuberculosis does not apparently reflect the
identical conditions of the blood serum responsible for a
" positive
" test in the
case of a number ofearly, new and untreated cancer patients. This report is not
an evaluation ofthedegree ofaccuracy ofthe method as a cancer diagnostic test.
METHOD AND MATERIAL.
The test was carried out exactly as described by Huggins, Miller and Jensen
(1949), except for a modification as suggested by them (private communication).
This was the use of a wireloop, 11 to 12 mm. in diameter, that was quickly thrust
into each test-tube after boiling the sera, to loosen the
" tenacious
" layer of
film ontop ofthe coagulum. The tube was inclined toapproximately a 45' angle,
to evaluate the degree ofclotting or liquification. Difficulties-in
" reading
" the
degree of clotting were mainly encountered in the new cancer cases. That is,
there appeared to be a higher incidence of transitional zones of the
" shapeless
viscous mass
)) type, than the clear-cut changes from clot to complete liquid that prevailed for the tuberculosis sera, the advanced treated cancer cases, and
the majority of benign tumour subjects and normal healthy persons. Readings
were doneby two personswithagreement onidentical tubes as to clots or complete liquification, and agreement within either of two tubes when considering the
96shapeless viscous mass
" type of coagulum. The factor which differentiates
one tube from another is that of the micromoles of sodium iodoacetate. This,
dividedby thereciprocal serumprotein percent, serves to fix thetype of
" index,"
or
lodoacetate Index (I.I.)
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where 0-5 ml. serum m micromoles of sodium iodoacetate in the nearest
tube containing a firm clot preceding a tube in which the coagulum is a
" shape-
less viscous mass,.. or in the ori inal state before boiling.
The serumprotein determinations were carried outby the semi-microKjeldahl
procedure recommended by Huggins, Miller and Jensen (1949). Every fifth
determination wasduplicated with an average agreement of ± 0-5 per cent. The
procedure was frequently checked for accuracy for the recovery of 5-0 mg.
quantities ofnitrogen by carrying out a complete determination with 23-6 mg.
quantities of anhydrous ammonium sulfate with recovery in duplicate being
0-02 to 0,03 mg. of nitrogen.
The source of the tuberculosis blood samples was the Harbor Hospital, Tor-
rence, and the cancerous, benign neoplasia, and non-symptomatic blood samples
were from our own clinic. All the tests reported here were done in the order in
which they were received. For purposes of analysis the cases are regrouped as
follows :
Group I consists of 46 biopsied, new, untreated cancer cases.
Group 1I consists of 36 advanced cancer cases in various stages of the
disease.
Group III consists of 55 pulmonary tuberculosis cases, of which 11 were
arrested.
Group IV consists of 92 biopsied benign growth-beating patients.
Group V consists of 85 non-symptomatic individuals.
The thermocoagulation : per cent ser-um protein relationship of the various
groups is represented graphically in Fig. 1.
It is necessary to comment on the clinical status of the various groups of
subjects. All tests were performed after the diagnosis had been established.
All the Group I patients were still in relatively good physical condition. None
of these cases tested were followed up for repeat determinations, except the two
comedocareinomas, which were done before surgery. None of the treated cancer
cases were H.M.J. tested (as we shall now refer to the test, since it was so desig-
nated by the authors) before treatment. The two myelomas were r-eceiving
nitrogen mustards ; the leucaemias, X-rays and/or transfusions ; some of the
advanced cases, polysaccharides or chymotrypsin ; eight of the breast cancer
cases, testosterone. None ofthe patients in Groups I and II received anyspecial
diet, except that the mostadvanced, uncontrolled cases weregetting eitherplasma
transfusions orproteinhydrolysates of one kind or another. All ofthem received
an iron-vitamin preparation. One of the II negative cases in Group III had an
acid-fast sputum at the time the H.M.J. test was done.
EXPERIMENTAL RESULTS.
Consideration of Table I shows the correlation of the serum protein per cent
with the I.I., as representative of the various groups of cases. Only 24 out of
46 or approximately 52 per cent of the Group I cases demonstrated a positive
H.M.J. (index less than 9-0), whereas 23 out of 36, or 63 per cent, of Group II,
and 44, or 80 per cent, ofGroup III, also yielded apositive H.M.J. At first hand
it would appear that the test was far more
" efficient
" in diagnosing tuberculosis
than cancer. However.4 it will be noted that the I.I. was derived from protein142 G. S. DUBOFF
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FiG. I.-Distribution ofiodoacetate indices andprotein content of serum. The horizontal line
represents theprotein values in g. per 100 ml. serum, and the vertical line the corresponding
indices, drawn from data. (D = positive segment; e
= negative segment of correlation.
0I, untreated cancer cases ; 0II, advanced cancer cases ; NIII, pulmonary tuberculosis;
xIV, benign neoplasms; 'WV, non-symptomatic controls.
TABLE I.-Summary of the Correspondence of Iodoacetate Index Range with the
Total Protein Range.
Number Iodoacetate Total
of cases. index. protein
per cent.
24 4- 7- 8- 8 . 6- 1-7- 7
22 9-0-13-8 . 5-9-6-8
Subjects.
Group I: Early cancer
II : Advanced cancer, treated, un-
controlled
Advanced cancer, treated, con-
trolled
III: Active pulmonary tuberculosis
Arrested pulmonary tubercu-
losis
IV: Benign neoplasia
V : Non-symptomatic normals
S 9 9 13
23 . 6- 2- 8- 1
13 . 9- 5-12- 2
44 . 5- 3- 7- 3
. 4-4-5- 7
6- 6-7- 5
4- 3-5- 1
6- 3-7- 2
5- 9-7- 6
5- 8-8- 1
6-2-8-2
6-5-6- 7
11
78
14
83
2
9- 3-11-4
9- 3-16-0
5-4- 8-4
9-3-11- 3
7- 7- 8- 9IODOACETATE INHIBITION OF THERMOCOAGULATION 143
values well within the normal range for this procedure in Group I, whilevirtually
the same I.I. range for Groups II and III was based upon a hypoproteinemia.
However, in those instances where the result was a negative H.M.J., regardless
of the clinical state, there was no such discrepancy in the serum protein values.
The observed variations in theproperties ofthe serum are detailed in Table 11,
and Table III is a breakdown of the types of growth encountered with indices
greater or less than 9,0.
A minor but interesting point emerging from our work is the fact that the
numerical values of the positive range of indices for Groups I and 11 is not due
TABLE II.-Frequency of Occurrence of Various Iodoacetate Indices in Different
Condition8.
Group I. Group II. Group III. Group IV. Group V.
lodoacetate. Untreated Advanced Pulmonary Benign Non-sympto-
index. cancer. cancer. tuberculosis. neoplasi.a. matic controls.
46 cases. 36 cases. 55 cases. 92 cases. 85 cases.
(Per cent.) (Per cent.) (Per cent.) (Per crnt.) (Per cent.)
4- 6- 5- 0 26- 1
5-i- 6-o 17-4 47-3 3 2
6-1- 7-0* 4-3 2"i-8 29.1 6-5
7.1- 8-0 2-2 16-7 3-6 1.1
8-1- 9-0 6.5 19-4 5-4 1.1
9.1-10-0 15.2 13-9 7-3 18-5 26-2
10.1-11-0 io-9 7-3 24-0 2-4
11-1-12-0 10-9 19-4 5-4 14-2 26-2
12-1-13-0 6-5 2-8 16-3 39-4
13-1-14-0 4-3 3-6
14-1-15-0 5-4
15-1-16-0 2-2
* This range of indices includes the average values of the two comedocarcinoma cases.
to the severity or extensiveness of the malignant process. Despite the so-called
6c precancerous
" nature of the two comedocarcinomas in Group 1, the degree
of
" positiveness
" was greater than for the lymphosarcoma and primary lung
adenocareinoma (I.I. between 8 and 9). The differential nature of the I.I. for
the series of cases in Group IV merely reflects the ratio of concentration of iodo-
acetate as an inhibitor of coagulation for decreasing quantities of serum protein.
There is no evidence that age distribution of the group tested played any signifi-
cant role in the ratios obtained for the I.I.
DISCUSSION
Analysis of the factors involved in the procedure showed that the coagula-
bility of 52 per cent of the Group I sera is abnormal for entirely different reasons
fromthe seraofGroups 11 andIII. Evidence forthislackofhomogeneitybetween
the protein values and the degree of positive H.M.J., obtained for tubercular
sera and the sera from new untreated cancer soon became apparent, i.e. the serum
protein ofthe positive I.I. ofthe tubercular sera did not he within the same range
ofprotein per cent for the new cancer cases as for the tubercular. Furthermore,144 GREGORY S. DUBOFF
TABLE III.-Di8tribution ofIodoacetate Indexfor Malignant andBenign Tumour8.
Group I: Maligmant tumours.
Comedocarcinoma, duct glands
Sarcoma, breast
Squamous ceR epithelioma lip
Adenocarcinoma nasopharynx
Lymphosarcoma
Malignant inelanoma
Leukaemia, lymphatic
Adenocarcinoma ovary
lung, bronchogenic
cervix
breast
Group IL
Multiple myeloma
Hodgkins
Adenocarcinoma thyroid
Lvmphosarcoma, stomach
Squamous cell epithehoma mouth
Adenocarcinoma rectum
Lymphosarcoma, tonsil
Adenocareinoma uterus
cervix, with metastases
breast
stomach
duodenum, with metastases
Iodacetate
index.
< 9.0. >9-(-
2
6 6
6 13
24 22
Iodoacetate
index.
<9.0. >9'-0.
2
3
1
1
2 3
4
6
2 1
4 1
2
1
23 13
Iodoacetate
index.
r---%--
<9-0. >9.0.
7 2
1 4
5
10
2 8
1 17
12
8
1 7
4
2 1
14 78
Group IV: Benign tumours.
Basal cell carcinoma .
Leukoplakia, mouth .
vagina
.
Cervical"polyps
fibrosis
Fibroid uteri
Pigmented verrucae
naevus
Keratosis
Sebaceous .c sts y
Cystic breast145 IODOACETATE INHIBITION OF T-HERMOCOAGULATION
when weattempted to substitute a morerapid and lesscostly method for estimat-
ing the serum protein, such as a viscosimetric procedure (Kagan, 1938 ; Phelps
and Van Slyke, 1943) our attempts met with faidure when relating the I.I. to the
Group I patients. In some the
" positive
" was altered to
"negative," and- in
others the positive results became more or less positive. There was good agree-
ment, however, for the I.I. values established by both Kjeldahl and falhng-drop
methods of protein estimations, for the remah-iing groups of cases. This led us
to consider an
" aberrant
" or
" combined-protein
" as being responsible for the
strikingdisagreement with the H.M.J. for the two types ofdisease.
The possibihty that we were deahng with an increase in one of the normal
fractions ofthe serum, thealphaglobulins,reportedto beincreasedinmahgnancy,
led us to carry out the test on a sample of mucoprotein from cancerous serum,
generouslysupphedby Dr. Richard Winzler, of the Department ofBiochemistry,
of the University of Southem Califomia, and a
" Bence Jones
" protein, isolated
from the urine of one ofthe two myeloma cases in this series. When adjusted to
anequivalentof 7
-0 g. per I00 ml. neither ofthesesubstancesyielded apositiveI.I.
If, as others haveobserved, thedegree ofincrease ofalphaglobuhn isproportional
to the severity of active tissue destruction, then apparently the alpha globulin
plays nopart intheHuggins test, eitherforadvancedtuberculosis,whichcertainly
involvesactive tissue destruction, or in the early and new untreated cancer cases
in our study.
The question of the existence of modified serum protein molecules in various
disease states, including mahgnancy, has been discussed recently by one ofthose
whose published data estabhshed a close correlation between plasma viscosity,
and the severity ofthe organic changes (Harkness, 1949). Added emphasis that
we may be dealing with an altered protein in malignant tumours is given by the
experimental observations ofHellwig (1949), who found that as a rule the size
ofspherical bodiesintheformofclusters, short-chainsandaggregatesfromtumour
extracts when examined by electron microscope wasexceeffinglylarger than that
in benign or normal tissue. He concludes that these globules are not virus-like
causative agents of cancer, but rather globular proteins, probable aggregates of
the cytoplasmic globules due to an alteration in the coHoidal state of the cancer
cell. It is quite possible that this cytoplasmic material may be introduced into
the blood serum and may play a role in accounting for the positive I.I. despite
a normal range of serum protein in the 24 cases ofGroup 1.
It is quite likely that those 'methods which measure the antiproteolytic
acti-vity (Clark, Cliffton and Newton, 1948), the rate of cell prohferatioii (Norris
and Majnarich, 1948, 1949), the enzyme: inhibiting or oxidation and reduction
(Duboff and Hirshfeld, 1946; Savignae, Gant and Sizer, 1944) inhibition of a
dyeby human serum in earlvmahgnant disease involve theproteins orsubstances
associated with the proteins ofthe serum.
Since the completion of this manuscript, Huggins, Jensen, Player and Hos-
pelborn (1949) havepubhshed observations whichsupport thetheory ofalteration
of the serum protein molecule in mahgnancy, by employing the binding of a
cationic dye. Only 44-7 per cent of their cases demonstrated a significantly
abnormal effect.
Huggins and his coReagues have demonstrated a valuable and fundamental
approach to the nature of these groups in health and disease. It is, however,
well to record that their method suffers from one serious drawback-the large
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subjective element in the estiniation of the coagulum. The task for the future
is the elimination of this factor, perhaps, by measuring the degree ofcoagulation
by an appropriate electronic procedure characterized by the electrical resistance
orpotential ofthe coagulum.
Can one explain the paradox of the 22 negative H.M.J. results in Group I ?
This question should be studied from the following approach: If the 24 positive
H.M.J. testshave a pattern ofdeformation in one direction, it is notinconceivable
that the former 22 cases have -a pattern of deformation in another direction that
is notmanifestedinthe testthroughthepresent combinationofreagents. Further-
more, if the mechanism of action of this method is due to the increase of net
negative charges on the protein molecule by the addition of sodium iodoacetate,
then our results strongly suggest variations in the polar character of the proteiii
molecule in the serum of certain phases of tumour development.
The magnitude ofrelationship between absolute protein per cent and the LL
demonstrated by Group III serum does not reflect the magnitude of the effect,
when apphed to Group I. The term
" false positive
" cannot be apphed' there-t
fore, to such tuberculosis sera, in the same sense as the term
" positive
" is Applied
to that ofearly cancerous sera, since the term
" positive
" itselfis not tenable- on
the same basis. The serum ofindividuals undergoing some type ofdegenerative
process, appears to possess an admixture of some elements, the source of which
we do not yet comprehend, but the presence of which has been demonstrated by
measurable function of the thermocoagulation of protein in the presence of an
extrinsic inhibitor, iodoacetate.
Tentatively, we are inclined toward the conclusiozi that abnormality in the
blood serum of some cancer patients, unhke that of some tuberculosis blood with
a corresponding I.I. (but not corresponding protein concentration), appears to
be the effect ofwholely or partiaUy altered configuration ofprotein molecules as
yet unidentified.
SUMMARY.
Human sera from new untreated and advanced treated cancer, from ad-
vanced and arrested tuberculosis, benign growths, and non-symptomatic healthy
persons were examined by a modified lodoacetate Index Test.
2. There was a decrease in the lodoacetate Index with corresponding decrease
in the serum values for 100 per cent of the advanced tubercular and 63 per cent
ofthe ad-vanced cancer cases.
3. However, there was also a decrease of the Iodoacetate Index without a
corresponding decrease in theseruni protein for 52 per cent of the sera of new, untreated cancer, 17 per cent of the benign tumours and 1-2 per cent ofthe non-
symptomatic controls.
4. The inhibited serum thermocoagulation phenomena in-volved in the Iodo-
acetate IndexTest appears to benon-specifiLc for active tuberculosis and advanced
cancer, but appears to be specific in certain early or new untreated mahgnancies and benign tumour growths.
5. It is suggested that the use ofthe expression
"false positive
" or
"Pseudo
-
positive" be elimiiaated from the terminology of cancer tests.
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